(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | -43.1MM | -225% |
Operating Income | -165.3MM | - |
Operating Expenses | 122.2MM | +13% |
Net Income | -154.8MM | - |
R&D | 95.1MM | +11% |
G&A | 27.1MM | +20% |
Amortization | 1.2MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.
Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas to gain access to the U.S. biotech firm's experimental prostate cancer drug, Arvinas said on Thursday. Shares of Connecticut-based Arvinas rose more than 6% to $39 in premarket trade. The pact adds to Novartis' pursuit of cancer treatments after it launched a tender offer on Thursday to acquire German cancer drugmaker MorphoSys for an aggregate 2.7 billion euros ($2.9 billion).
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties – – Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 – – Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatmen
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a member of the Executive Committee reporting to President and Chief Executive Officer John Houston, Ph.D. Eff
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners Global Biopharma Conference on Tuesday, March 12. Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in a fireside chat. A live audio webcast
It's shaping up to be a tough period for Arvinas, Inc. ( NASDAQ:ARVN ), which a week ago released some disappointing...
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -90.23% and 210.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?